467 research outputs found

    Orbital tuberculosis in childhood with intracranial extension: a case report

    Get PDF
    The common causes of orbital masses in pediatric age group include pseudotumour, lymphomas, hemangioma and dermoid cyst. Orbital tuberculosis is rare especially in children. We report a case of 5 year old child who presented with proptosis and gross diminution of vision due to orbital tuberculoma. Ocular examination of the left eye revealed proptosis with the eyeball displaced downwards and forwards. Vision was counting finger close to face. CT Scan showed an extraconal soft tissue mass along posteromedial side of left orbit with lateral displacement of medial rectus muscle. On antitubercular treatment, proptosis regressed and visual recovery was observed over a period of six month vision, in the left eye at the last followup was 20/30

    AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation

    Get PDF
    SummaryWhile allosteric activation of AMPK is triggered only by AMP, binding of both ADP and AMP has been reported to promote phosphorylation and inhibit dephosphorylation at Thr172. Because cellular concentrations of ADP and ATP are higher than AMP, it has been proposed that ADP is the physiological signal that promotes phosphorylation and that allosteric activation is not significant inĀ vivo. However, we report that: AMP is 10-fold more potent than ADP in inhibiting Thr172 dephosphorylation; only AMP enhances LKB1-induced Thr172 phosphorylation; and AMP can cause >10-fold allosteric activation even at concentrations 1ā€“2 orders of magnitude lower than ATP. We also provide evidence that allosteric activation by AMP can cause increased phosphorylation of acetyl-CoA carboxylase in intact cells under conditions in which there is no change in Thr172 phosphorylation. Thus, AMP is a true physiological regulator of AMPK, and allosteric regulation isĀ an important component of the overall activation mechanism

    1,2,6-thiadiazinones as novel narrow spectrum calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) inhibitors

    Get PDF
    We demonstrate for the first time that 4H-1,2,6-thiadiazin-4-one (TDZ) can function as a chemotype for the design of ATP-competitive kinase inhibitors. Using insights from a co-crystal structure of a 3,5-bis(arylamino)-4H-1,2,6-thiadiazin-4-one bound to calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2), several analogues were identified with micromolar activity through targeted displacement of bound water molecules in the active site. Since the TDZ analogues showed reduced promiscuity compared to their 2,4-dianilinopyrimidine counter parts, they represent starting points for development of highly selective kinase inhibitors

    Establishing Foundation Archives: A Reader and Guide to First Steps

    Get PDF
    This publication is an anthology of papers presented at a conference held at the Rockefeller Archive Center in January 1990, and sponsored by the Council on Foundations. This collaboration of the Archive Center and the Council provided a rare opponunity for foundations to learn both why preserving documents is imponant and how several foundations have approached finding a repository or setting up and managing an archives. Participants in the conference had the added privilege of conferring with experts and seeing an operating archive as they toured the Rockefeller Archive Center.Foundations are institutions that are shaping private initiatives for the public good, so documenting this aspect of American society falls uniquely under the stewardship of the organizations themselves. Foundation documents often provide the only surviving records of the important contributions of nonprofits and foundations to civic life. These records will help to inform future judgments and ensure that the history of the field is not lost. The publication of this volume was intended to make the information shared at the conference more widely available and to provide an entry point and a primer for foundations as they begin their records and archives journey

    AMP-activated protein kinase complexes containing the Ī²2 regulatory subunit are upregulated during and contribute to adipogenesis

    Get PDF
    AMP-activated protein kinase (AMPK) is a heterotrimer of Ī± catalytic and Ī² and Ī³ regulatory subunits that acts to regulate cellular and whole-body nutrient metabolism. The key role of AMPK in sensing energy status has led to significant interest in AMPK as a therapeutic target for dysfunctional metabolism in type 2 diabetes, insulin resistance and obesity. Despite the actions of AMPK in liver and skeletal muscle being extensively studied, the role of AMPK in adipose tissue and adipocytes remains less well characterised. Small molecules that selectively influence AMPK heterotrimers containing specific AMPKĪ² subunit isoforms have been developed, including MT47-100, which selectively inhibits complexes containing AMPKĪ²2. AMPKĪ²1 and AMPKĪ²2 are the principal AMPKĪ² subunit isoforms in rodent liver and skeletal muscle respectively, yet the contribution of specific AMPKĪ² isoforms to adipose tissue function, however, remains largely unknown. This study therefore sought to determine the contribution of AMPKĪ² subunit isoforms to adipocyte biology, focussing on adipogenesis. AMPKĪ²2 was the principal AMPKĪ² isoform in 3T3-L1 adipocytes, isolated rodent adipocytes and human subcutaneous adipose tissue, as assessed by the contribution to total cellular AMPK activity. Downregulation of AMPKĪ²2 with siRNA inhibited lipid accumulation, cellular adiponectin levels and adiponectin secretion during 3T3-L1 adipogenesis, whereas downregulation of AMPKĪ²1 had no effect. Incubation of 3T3-L1 cells with MT47-100 selectively inhibited AMPK complexes containing AMPKĪ²2 whilst simultaneously inhibiting cellular lipid accumulation as well as cellular levels and secretion of adiponectin. Taken together, these data indicate that increased expression of AMPKĪ²2 is an important feature of efficient adipogenesis

    Impact of genetic variation on human CaMKK2 regulation by Ca2+ -calmodulin and multisite phosphorylation

    Get PDF
    The Ca2+-calmodulin dependent protein kinase kinase-2 (CaMKK2) is a key regulator of neuronal function and whole-body energy metabolism. Elevated CaMKK2 activity is strongly associated with prostate and hepatic cancers, whereas reduced CaMKK2 activity has been linked to schizophrenia and bipolar disease in humans. Here we report the functional effects of nine rare-variant point mutations that were detected in large-scale human genetic studies and cancer tissues, all of which occur close to two regulatory phosphorylation sites and the catalytic site on human CaMKK2. Four mutations (G87R, R139W, R142W and E268K) cause a marked decrease in Ca2+-independent autonomous activity, however S137L and P138S mutants displayed increased autonomous and Ca2+-CaM stimulated activities. Furthermore, the G87R mutant is defective in Thr85-autophosphorylation dependent autonomous activity, whereas the A329T mutation rendered CaMKK2 virtually insensitive to Ca2+-CaM stimulation. The G87R and R139W mutants behave as dominant-negative inhibitors of CaMKK2 signaling in cells as they block phosphorylation of the downstream substrate AMP-activated protein kinase (AMPK) in response to ionomycin. Our study provides insight into functionally disruptive, rare-variant mutations in human CaMKK2, which have the potential to influence risk and burden of disease associated with aberrant CaMKK2 activity in human populations carrying these variants

    Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding

    Get PDF
    The metabolic stress-sensing enzyme AMP-activated protein kinase (AMPK) is responsible for regulating metabolism in response to energy supply and demand. Drugs that activate AMPK may be useful in the treatment of metabolic diseases including type 2 diabetes. We have determined the crystal structure of AMPK in complex with its activator 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid (C2), revealing two C2-binding sites in the Ī³-subunit distinct from nucleotide sites. C2 acts synergistically with the drug A769662 to activate AMPK Ī±1-containing complexes independent of upstream kinases. Our results show that dual drug therapies could be effective AMPK-targeting strategies to treat metabolic diseases

    Differential regulation by AMP and ADP of AMPK complexes containing different Ī³ subunit isoforms

    Get PDF
    The Ī³ subunits of heterotrimeric AMPK complexes contain the binding sites for the regulatory adenine nucleotides AMP, ADP and ATP. We addressed whether complexes containing different Ī³ isoforms display different responses to adenine nucleotides by generating cells stably expressing FLAG-tagged versions of the Ī³ 1, Ī³ 2 or Ī³ 3 isoform. When assayed at a physiological ATP concentration (5 mM), Ī³ 1- and Ī³ 2-containing complexes were allosterically activated almost 10-fold by AMP, with EC50 values one to two orders of magnitude lower than the ATP concentration. By contrast, Ī³ 3 complexes were barely activated by AMP under these conditions, although we did observe some activation at lower ATP concentrations. Despite this, all three complexes were activated, due to increased Thr172 phosphorylation, when cells were incubated with mitochondrial inhibitors that increase cellular AMP. With Ī³ 1 complexes, activation and Thr172 phosphorylation induced by the upstream kinase LKB1 [liver kinase B1; but not calmodulin-dependent kinase kinase (CaMKKĪ²)] in cell-free assays was markedly promoted by AMP and, to a smaller extent and less potently, by ADP. However, effects of AMP or ADP on activation and phosphorylation of the Ī³ 2 and Ī³ 3 complexes were small or insignificant. Binding of AMP or ADP protected all three Ī³ subunit complexes against inactivation by Thr172 dephosphorylation; with Ī³ 2 complexes, ADP had similar potency to AMP, but with Ī³ 1 and Ī³ 3 complexes, ADP was less potent than AMP. Thus, AMPK complexes containing different Ī³ subunit isoforms respond differently to changes in AMP, ADP or ATP. These differences may tune the responses of the isoforms to fit their differing physiological roles
    • ā€¦
    corecore